Do we have the right priorities in oncology #ESMO2023 #ESMO23 - pictures taken a few minutes apart. Supportive care and Investigational therapy poster areas. Clinically these two are intertwined.

Peter B. Bach, MD Supportive care - hard work for doctors, no Pharma money , no fancy NEJM publications written by Pharma , no speaking engagements Till all of that is fixed doubt supportive care will get the due credit it deserves

The burnout epidemic CANNOT be resolved with self care. It is job related. Hospital executives must improve working conditions : reduce template size, number of clicks in EHR, increase time with patients, appoint leaders who like and value clinical care.

📘Geriatric assessment in oncology CA: A Cancer Journal for Clinicians ✅Predictive models for toxicity👇 ✅Geriatric assessment improves outcomes👇 ✅A practical geriatric assessment table👇 ✅Barriers and how to overcome 👉doi.org/10.3322/caac.2… ESMO - Eur. Oncology American Geriatrics Society British Geriatrics Society OncoAlert

I to je upravo ono što radimo na IORS kada procenjujemo podobnost starijih pacijenata za hemioterapiju

Veoma koristan komadic slagalice. Miokarditis kao najsmrtonosniji irAEs

Clinical+genetic factors assoc with Type I diabetes from ICIs JAMA Oncology: - Of 14328pts, incidence 0.45% - 3 phenotypes of T1DM exist, based on Ab & C-peptide(B): Ab+B-=earlier onset, ⬆️DKA - T1DGRS2 polygenic risk score= 4.4fold ⬆️risk OncoAlert #LCSM ja.ma/3MoT9xH

Redefining priorities: a call for patient-centred #cancer care and research. nature.com/articles/s4157… nature Nature Medicine NatureRevClinOncol Nature Reviews Cancer #CancerResearch #CancerCare #PallOnc #SuppOnc

A must-read patient/survivor/advocate perspective shedding light on the need to redefine priorities in cancer care and research. nature.com/articles/s4157… NatureRevClinOncol

🌍 We are delighted to announce the 12 new Designated Centres accredited in 2024 from 9 countries. 🔗 Find out more here👉 ow.ly/2Mmz50TcXj5 #palliativecare #supportivecare

@JCO article demonstrating AI-based large language models to identify #irAEs among hospitalized patients ASCO #immunotherapy #ASPirE Pauline Funchain Kerry Reynolds ascopubs.org/doi/pdf/10.120…

📢**Save the date**📢 Our first ASCO #PallOncCoP kick off event feat. Ramy Sedhom, MD will be starting on Thurs Sept 26th at 4p EST. DM for 💻Zoom🔗or listerv add✉️ Fionnuala Crowley Mazie Tsang, MD, MAS, MS Darcy Burbage, DNP, RN, AOCN Dr Joseph McCollom DO Ramy Sedhom, MD Tingting Zhang Jafar Al-Mondhiry, MD, MA Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

"It’s important that we co-develop strategies to minimize toxicities because patients are living with these effects, and they have equal importance in the development of drugs.” - Eric Roeland, MD, FASCO, FAAHPM on OHSU Knight Cancer Institute's “Symptom Science” program (via Healio): healio.com/news/hematolog…

Thank you Jill Feldman ! Honored to present on palliative care for people with advanced lung cancer in an advanced cancer survivorship session at #WCLC2024 today

Great Symposium Common Sense Oncology Common Sense Oncology at #ESMO2024. A little overwhelmed😅 to share table with speaker such Dario Trapani Bishal Gyawali and WinetteVanDerGraaf, and the presence in the audience of EORTC president, last #ASCO president Lynn Schuchter, and ASCO CMO Julie Gralow

A positive trial for cancer cachexia - a very distressing symptom to patients and caregivers! Congrats to my bud Eric Roeland, MD, FASCO, FAAHPM for being an NEJM author

NEJM RCT phase II study of ponsegromab (anti-GDF-15) vs placebo with increased weight gain, improved appetite and symptoms, and improved physical activity without increased AEs in people living with advanced lung and GI cancers. New findings in a critical unmet need! ASCO

#ESMO24 Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized LEANOX trial 💥Oxaliplatin dosing based on lean body mass reduces neuropathy without compromising survival

This study suggests that ponsegromab may be a potential agent for the management of cachexia. However, it remains unclear whether it is superior to the currently available options, such as olanzapine or megestrol, which are recommended as optional treatments by ASCO. If the

My top list of phrases that are not really patient friendly. #ESMO24 ❌ Grade 5 Events 🤨 ❌ AEs being manageable/tolerable 🥱 ❌ How to manage patients 😬 ❌ Patients = Subjects 🙄 ❌ Not clinically meaningful 🤔 Anyone want to continue the list? OncoAlert